News | Swixx BioPharma | Modern Medicines for All

News

News Archive

• 2026
  • Feb 3, 2026 Swixx and Madrigal Announce Exclusive European Partnership on First Targeted Therapy for MASH
  • Mar 4, 2026 Swixx BioPharma Expands Partnership With Eli Lilly to Brazil
  • Mar 30, 2026 Swixx Enters Into a Strategic Multiregional Distribution Partnership With BridgeBio
  • Jun 1, 2026 Swixx Completes Strategic Investment From SK Capital and Bain Capital Life Sciences to Support Continued Global Expansion
  • Jun 10, 2026 Swixx Biopharma Earns EcoVadis Silver Medal, Ranking Among the Top 15% Globally
  • Jun 29, 2026 Swixx Named One of Switzerland's Best Managed Companies for Second Consecutive Year
  • Jul 22, 2026 Swixx Welcomes Martin Dewhurst as Independent Director
• 2025
  • Mar 17, 2025 Biopas, a Swixx Biopharma Company, Expands UCB Partnership with Additional Brands
  • Apr 28, 2025 Swixx and Biopas Expand Portfolio in Latin America, Securing 9 New Partnership Contracts in One Year
  • Jul 4, 2025 Swixx Named As One of Best Managed Companies by Deloitte
  • Sep 10, 2025 Lundbeck Selects Swixx as a Key Partner in a Transformative Multi-Regional Deal
  • Dec 1, 2025 Swixx and Lundbeck Partnership Goes Live
  • Dec 15, 2025 SK Capital Invests in Swixx Biopharma to Accelerate Global Expansion
• 2024
  • Mar 6, 2024 Swixx BioPharma recognized in the 2024 FT1000 list - One of Europe’s fastest- growing companies
  • May 22, 2024 Swixx BioPharma Expands to Latin America Through a Strategic Acquisition and Combination With Biopas
  • Jul 4, 2024 Swixx Biopharma Formally Closes the Deal with Biopas, Expanding to Latin America
  • Sep 5, 2024 Swixx BioPharma Publishes ESG Strategy Framework
  • Sep 23, 2024 Pharma’s New Frontiers: Strategic Outsourcing for Long-term Global Growth
  • Sep 25, 2024 Swixx Signs Agreement with Krystal Biotech for Vyjuvek® Gene Therapy for The Treatment of Dystrophic Epidermolysis Bullosa
• 2023
  • Jan 3, 2023 Swixx and Otsuka Expand Partnership
  • Jan 20, 2023 Swixx and Jazz Pharmaceuticals Expand Partnership in CEE Territories
  • Jan 24, 2023 Swixx and BioCryst Partner in Central and Eastern Europe
  • May 8, 2023 Swixx appoints Marek Vasicek, MD, Chief Operating Officer Russia / Eurasia and R.O.W. (Rest of World) Expansion
  • May 9, 2023 Swixx and BeiGene partner in 13 countries of Central and Eastern Europe, Greece, Cyprus and Malta
  • Jul 17, 2023 Swixx Reveals Refreshed Corporate Visual and Website
  • Sep 18, 2023 Swixx BioPharma Announcement of MENA Expansion Appointment of Manar Al Nahar
• 2022
  • Apr 11, 2022 Swixx signs deal with Blueprint Medicines
  • Apr 19, 2022 Swixx and Jazz Pharmaceuticals Expand Partnership
  • Oct 10, 2022 Swixx and Kyowa Kirin Enter into Partnership for Rare Disease Medicines Portfolio in Poland
  • Dec 19, 2022 Swixx and Kyowa Kirin Expand Partnership for Rare Disease to 13 Countries in Europe
• 2021
  • Feb 5, 2021 Swixx Completed Additional Eleven Business Development Deals in 2021
  • Mar 1, 2021 Swixx Signs Regional Agreement with SeaGen
  • Mar 4, 2021 Swixx Biopharma Announcment - Syndicated Loan Facility
  • Mar 15, 2021 Swixx and Jazz Pharmaceuticals Sign CEE Deal
  • May 20, 2021 Merieux Equity Partners Invests as Swixx raises 45 Million Euros
  • Sep 14, 2021 Pavel Chistyakov Appointed Regional Director Russia CIS Eurasia
  • Oct 4, 2021 Swixx establishes Greek Affiliate and Appoints George Bithas GM
  • Dec 3, 2021 Swixx and Jazz Add Poland in 2nd CEE Deal
  • Dec 13, 2021 Swixx Signs Exclusive Distribution Contract with Sanofi Covering 14 Countries
  • Dec 16, 2021 Swixx Becomes Gilead Partner in Baltic Republics
• 2020
  • Feb 13, 2020 Swixx to represent Norgine in CEE
  • Feb 17, 2020 Swixx Contracts with Alk in West Balkans
  • Mar 25, 2020 Swixx and Vifor Sign a Deal for Slovakia
  • Mar 30, 2020 Swixx signs deal with UPSA for Russia
  • Sep 3, 2020 Swixx and Norgine Sign Distribution Deal for CEE
  • Dec 18, 2020 Swixx and Y-mAbs sign CEE Distribution Deal